JP2024502479A5 - - Google Patents

Info

Publication number
JP2024502479A5
JP2024502479A5 JP2023541867A JP2023541867A JP2024502479A5 JP 2024502479 A5 JP2024502479 A5 JP 2024502479A5 JP 2023541867 A JP2023541867 A JP 2023541867A JP 2023541867 A JP2023541867 A JP 2023541867A JP 2024502479 A5 JP2024502479 A5 JP 2024502479A5
Authority
JP
Japan
Prior art keywords
polynucleotide according
variant
functional fragment
polynucleotide
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023541867A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024502479A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/011878 external-priority patent/WO2022150732A2/en
Publication of JP2024502479A publication Critical patent/JP2024502479A/ja
Publication of JP2024502479A5 publication Critical patent/JP2024502479A5/ja
Pending legal-status Critical Current

Links

JP2023541867A 2021-01-11 2022-01-10 キメラ受容体療法 Pending JP2024502479A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202163136074P 2021-01-11 2021-01-11
US63/136,074 2021-01-11
US202163136611P 2021-01-12 2021-01-12
US63/136,611 2021-01-12
US202163263001P 2021-10-25 2021-10-25
US63/263,001 2021-10-25
US202163263508P 2021-11-03 2021-11-03
US63/263,508 2021-11-03
PCT/US2022/011878 WO2022150732A2 (en) 2021-01-11 2022-01-10 Chimeric receptor therapy

Publications (2)

Publication Number Publication Date
JP2024502479A JP2024502479A (ja) 2024-01-19
JP2024502479A5 true JP2024502479A5 (enExample) 2025-01-20

Family

ID=82322745

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023541867A Pending JP2024502479A (ja) 2021-01-11 2022-01-10 キメラ受容体療法

Country Status (9)

Country Link
US (1) US20220220187A1 (enExample)
EP (1) EP4274898A4 (enExample)
JP (1) JP2024502479A (enExample)
KR (1) KR20230143140A (enExample)
AU (1) AU2022205683A1 (enExample)
CA (1) CA3204211A1 (enExample)
IL (1) IL304292A (enExample)
MX (1) MX2023008115A (enExample)
WO (1) WO2022150732A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11771718B2 (en) * 2017-10-18 2023-10-03 Precigen, Inc. Polypeptide compositions comprising spacers
GB202201927D0 (en) * 2022-02-14 2022-03-30 Kings College Artificial microrna construct
CA3261027A1 (en) * 2022-07-10 2024-01-18 Precigen, Inc. POLYCISTRONIC miRNA CONSTRUCTS FOR IMMUNE CHECKPOINT INHIBITION
CN121909290A (zh) * 2023-07-10 2026-04-21 普瑞赛格恩公司 α-1抗胰蛋白酶缺乏症的治疗
WO2025029865A1 (en) * 2023-07-31 2025-02-06 Precigen, Inc. Cd19-targeted car t cell therapy
WO2025101959A1 (en) * 2023-11-08 2025-05-15 Renbio, Inc. Plasmid dna constructs for peptide hormone expression
US12435338B2 (en) 2023-11-22 2025-10-07 Wyvern Pharmaceuticals Inc. Composition for regulating production of interfering ribonucleic acid
WO2025137580A1 (en) * 2023-12-22 2025-06-26 Antiger Therapeutics, Inc. Class ii hla with inter-chain disulfide bond

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3783098A1 (en) * 2013-05-14 2021-02-24 Board Of Regents, The University Of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
CN106061488B (zh) * 2013-12-02 2021-04-09 菲奥医药公司 癌症的免疫治疗
CA3012344A1 (en) * 2016-02-12 2017-08-17 University Of Massachusetts Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
CA3065930A1 (en) * 2017-06-07 2018-12-13 Intrexon Corporation Expression of novel cell tags
US11771718B2 (en) * 2017-10-18 2023-10-03 Precigen, Inc. Polypeptide compositions comprising spacers
US11649455B2 (en) * 2018-03-30 2023-05-16 University Of Geneva Micro RNA expression constructs and uses thereof
CA3105816A1 (en) * 2018-07-10 2020-01-16 Precigen, Inc. Ror-1 specific chimeric antigen receptors and uses thereof
EP3963076A1 (en) * 2019-05-02 2022-03-09 Celyad Cells with multiplexed inhibitory rna

Similar Documents

Publication Publication Date Title
JP2024502479A5 (enExample)
JP7735373B2 (ja) 多鎖キメラポリペプチドおよびその使用
CN112300269B (zh) Kras突变特异性t细胞受体筛选及抗肿瘤用途
JP2019525914A5 (enExample)
JP2021177771A5 (enExample)
JP2023505492A5 (enExample)
JP2016514457A5 (enExample)
JP2019527055A5 (enExample)
JP2014221758A5 (enExample)
JP2020500510A5 (enExample)
JP2015212284A5 (enExample)
JP2021531265A5 (enExample)
JP2019530441A5 (enExample)
IL292650B2 (en) COSTIMULATORY CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING IL13Ra2
JPH08510756A (ja) ストレス蛋白質とその使用
JP2018524987A5 (enExample)
JP2014508748A5 (enExample)
JP2008525033A5 (enExample)
JP2021524275A5 (enExample)
JP2015524413A5 (enExample)
Guo et al. γδ T cell antigen receptor polyspecificity enables T cell responses to a broad range of immune challenges
JP2020532285A5 (enExample)
CN114736291B (zh) 特异性结合发热伴血小板减少综合征病毒的囊膜蛋白Gn的人源单克隆抗体及其用途
CN111542546A (zh) 抗lag-3 抗体及其用途
JP2020512284A5 (enExample)